Drug intelligence / Profile preview

LNL007

Development stage: Unknown
Lead developer: L&L Biopharma
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

LNL007 is a chimeric antigen receptor (CAR) T-cell therapy being developed by L&L Biopharma for the treatment of solid tumors. The therapy involves the genetic modification of T cells to express a CAR that recognizes an undisclosed tumor-associated antigen. LNL007 is currently in Phase 1 clinical development, specifically through investigator-initiated trials (IIT), to evaluate its safety and therapeutic potential in patients with various solid malignancies.

Beyond the preview

Go deeper on LNL007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNL007.

Explore the full profile